Outcomes | IFX group | Placebo group | All patients | p-value |
---|---|---|---|---|
n = 18 | n = 17 | n = 35 | ||
Day 0 after injection | ||||
Absolute VAS change, median (IQR) | −26.8 (–54.8 to –14.3) | −56.7 (–73.3 to –28.6) | −36.0 (–72.3 to –14.3) | 0.22 |
50 % reduction in sciatica pain, n (%) | 5 (27.8) | 9 (52.9) | 14 (40.0) | 0.13 |
PASS <40 mm, n (%) | 5 (27.8) | 12 (70.6) | 17 (48.6) | 0.01* |
MCII ≥15 mm, n (%) | 12 (66.7) | 13 (76.5) | 25 (71.4) | 0.52 |
MCII ≥20 %, n (%) | 11 (61.1) | 13 (76.5) | 24 (68.6) | 0.33 |
Day 10 after injection | ||||
Absolute VAS change, median (IQR) | −14.9 (–50.0 to 3.3) | 0.0 (–30.9 to 10.0) | −9.2 (–38.5 to 9.1) | 0.21 |
50 % reduction in sciatica pain, n (%) | 5 (27.8) | 3 (17.6) | 8 (22.9) | 0.69 |
PASS <40 mm, n (%) | 4 (22.2) | 4 (23.5) | 8 (22.9) | 0.94 |
MCII ≥15 mm, n (%) | 9 (50.0) | 5 (29.4) | 14 (40.0) | 0.21 |
MCII ≥20 %, n (%) | 8 (44.4) | 5 (29.4) | 13 (37.1) | 0.36 |